Evidence map›Paper›PMID 31256020›Full record

ArticleBMJ open2019

Cybersecurity features of digital medical devices: an analysis of FDA product summaries.

Ariel Dora Stern, William J Gordon, Adam B Landman, Daniel B Kramer

Abstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Developing a medical-device formulary for council of health insurance beneficiaries in Saudi Arabia: stakeholder challenges and policy recommendations.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. A scoping review and expert consensus on digital determinants of health.Bulletin of the World Health Organization · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Strengthening Cybersecurity for Patient Data Protection in Europe.Journal of medical Internet research · 2023
    Article
  12. Digital therapeutics in the clinic.Bioengineering & translational medicine · 2023
    Review
  13. Current challenges for evaluating mobile health applications.Journal of the American Medical Informatics Association : JAMIA · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021
    Article
  19. Article
  20. Should Medical Devices Be Regulated as Rigorously as Drugs?The Canadian journal of hospital pharmacy
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ariel Dora SternHarvard Business School Technology and Operations Management, Boston, Massachusetts, USA.ORCID 0000-0002-3586-1041
William J GordonBrigham and Women's Hospital Department of Medicine, Boston, Massachusetts, USA.
Adam B LandmanBrigham and Women's Hospital Department of Medicine, Boston, Massachusetts, USA.
Daniel B KramerHarvard Medical School, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo more clearly define the landscape of digital medical devices subject to US Food and Drug Administration (FDA) oversight, this analysis leverages publicly available regulatory documents to characterise the prevalence and trends of software and cybersecurity features in regulated medical devices.

designWe analysed data from publicly available FDA product summaries to understand the frequency and recent time trends of inclusion of software and cybersecurity content in publicly available product information.

settingThe full set of regulated medical devices, approved over the years 2002-2016 included in the FDA's 510(k) and premarket approval databases. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was the share of devices containing software that included cybersecurity content in their product summaries. Secondary outcomes were differences in these shares (a) over time and (b) across regulatory areas.

resultsAmong regulated devices, 13.79% were identified as including software. Among these products, only 2.13% had product summaries that included cybersecurity content over the period studied. The overall share of devices including cybersecurity content was higher in recent years, growing from an average of 1.4% in the first decade of our sample to 5.5% in 2015 and 2016, the most recent years included. The share of devices including cybersecurity content also varied across regulatory areas from a low of 0% to a high of 22.2%.

conclusionsTo ensure the safest possible healthcare delivery environment for patients and hospitals, regulators and manufacturers should work together to make the software and cybersecurity content of new medical devices more easily accessible.

Indexed as

Computer SecurityEquipment and SuppliesProduct Surveillance, PostmarketingUnited States Food and Drug AdministrationDevice ApprovalUnited StatescybersecurityFDAmedical devicessoftware

Identifiers

PMID31256020
PMCPMC6609083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.